Literature DB >> 28186264

Predictive performance of eleven pharmacokinetic models for propofol infusion in children for long-duration anaesthesia.

M Hara1, K Masui2, D J Eleveld3, M M R F Struys3,4, O Uchida1.   

Abstract

Background: Predictive performance of eleven published propofol pharmacokinetic models was evaluated for long-duration propofol infusion in children.
Methods: Twenty-one aged three-11 yr ASA I-II patients were included. Anaesthesia was induced with propofol or sevoflurane, and maintained with propofol, remifentanil, and fentanyl. Propofol was continuously infused at rates of 4-14 mg kg  - 1 h - 1 after an initial bolus of 1.5-2.0 mg kg  - 1 . Venous blood samples were obtained every 30-60 min for five h and then every 60-120 min after five h from the start of propofol administration, and immediately after the end of propofol administration. Model performance was assessed with prediction error (PE) derivatives including divergence PE, median PE (MDPE), and median absolute PE (MDAPE) as time-related PE shift, measures for bias, and inaccuracy, respectively.
Results: We collected 85 samples over 270 (130) (88-545), mean (SD) (range), min. The Short model for children, and the Schüttler general-purpose model had acceptable performance (-20%≤MDPE ≤ 20%, MDAPE ≤ 30%, -4% h - 1  ≤   divergence PE ≤ 4% h - 1 ). The Short model showed the best performance with the maximum predictive performance metric. Two models developed only using bolus dosing (Shangguan and Saint-Maurice models) and the Paedfusor of the remaining nine models had significant negative divergence PE (≤-6.1% h - 1 ). Conclusions: The Short model performed well during continuous infusion up to 545 min. This model might be preferable for target-controlled infusion for long-duration anaesthesia in children.
© The Author 2017. Published by Oxford University Press on behalf of the British Journal of Anaesthesia. All rights reserved. For Permissions, please email: journals.permissions@oup.com

Entities:  

Keywords:  paediatrics; pharmacokinetics; propofol

Mesh:

Substances:

Year:  2017        PMID: 28186264     DOI: 10.1093/bja/aex007

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  4 in total

1.  Dexmedetomidine in Children on Extracorporeal Membrane Oxygenation: Pharmacokinetic Data Exploration Using Previously Published Models.

Authors:  Céline Thibault; Athena F Zuppa
Journal:  Front Pediatr       Date:  2022-06-27       Impact factor: 3.569

2.  The use of PBPK modeling across the pediatric age range using propofol as a case.

Authors:  Robin Michelet; Jan Van Bocxlaer; Karel Allegaert; An Vermeulen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-10-08       Impact factor: 2.745

3.  Model Re-Estimation: An Alternative for Poor Predictive Performance during External Evaluations? Example of Gentamicin in Critically Ill Patients.

Authors:  Alexandre Duong; Chantale Simard; David Williamson; Amélie Marsot
Journal:  Pharmaceutics       Date:  2022-07-07       Impact factor: 6.525

Review 4.  Clinical Pharmacokinetics and Pharmacodynamics of Propofol.

Authors:  Marko M Sahinovic; Michel M R F Struys; Anthony R Absalom
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.